期刊
AMINO ACIDS
卷 44, 期 1, 页码 45-51出版社
SPRINGER WIEN
DOI: 10.1007/s00726-012-1278-y
关键词
Human prostate cancer; Transglutaminase; Cyclins; Vitamin E
To establish a system to study differentiation therapy drugs, we used the androgen-independent human prostate PC-3 tumor cell line as a target and alpha- and gamma-tocopherol as inducers. Effects of alpha- and gamma-tocopherol on the cell cycle, proliferation and differentiation, were examined. A more significant growth inhibition activity for gamma- than for alpha-tocopherol was observed. Flow cytometry analysis of alpha- and gamma-tocopherol-treated prostate carcinoma PC3 cells showed decreased progression into the S-phase. This effect, particularly evident for gamma-tocopherol, was associated with an up-regulation and increased activity of transglutaminase 2 (TG2), a reduced DNA synthesis and a remarkable decreased levels of cyclin D1 and cyclin E. Activation of TG2 suggests that gamma-tocopherol has an evident differentiative capacity on PC3 cells, leading to an increased expression of TG2, and reduced cyclin D1 and cyclin E levels, affecting cell cycle progression. It is feasible that up-regulation and activation of TG2, associated with a reduced proliferation, are parts of a large-scale reprogramming that can attenuate the malignant phenotype of PC3 cells in vitro. These data suggest further investigation on the potential use of this gamma-form of vitamin E as a differentiative agent, in combination with the common cytotoxic treatments for prostate cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据